Carcinoid Syndrome
6
Pipeline Programs
4
Companies
6
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
2
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
150%
Peptide
150%
+ 4 programs with unclassified modality
On Market (1)
Approved therapies currently available
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Crinetics PharmaceuticalsSAN DIEGO, CA
2 programs1
1
1
PaltusotinePhase 31 trial
Randomized: 40 mg PaltusotinePhase 21 trial
Active Trials
IpsenChina - Tianjin
2 programs1
1
LanreotidePhase 3Peptide1 trial
BIM 23A760Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Crinetics PharmaceuticalsPaltusotine
IpsenLanreotide
Crinetics PharmaceuticalsRandomized: 40 mg Paltusotine
AmgenPanitumumab
IpsenBIM 23A760
TerSera TherapeuticsXermelo
Clinical Trials (6)
Total enrollment: 300 patients across 6 trials
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Start: Nov 2025Est. completion: Jan 2030141 patients
Phase 3Recruiting
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Start: May 2009Est. completion: Dec 2015115 patients
Phase 3Completed
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Start: Apr 2022Est. completion: Feb 202636 patients
Phase 2Active Not Recruiting
Study of Panitumumab in the Treatment of Carcinoid Syndrome
Start: Jul 2013Est. completion: Jul 20130
Phase 2Withdrawn
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Start: Feb 2010Est. completion: Jan 20118 patients
Phase 2Terminated
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Start: Jun 2017Est. completion: Jan 2022
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 300 patients
4 companies competing in this space